This common day-surgery investigation requires fasting beforehand and usually involves sedation for patient comfort, with a recovery time of about 15-20 minutes for the procedure itself, yet despite the procedure, many EAC cases are still not identified in time.
PromarkerEso works by analysing protein biomarkers in the blood alongside other key clinical factors such as age, sex and body mass index, to deliver a straightforward risk score to guide the need for and urgency of further investigation.
In short, the test offers a simpler, non-invasive alternative and has shown strong accuracy in identifying EAC in clinical studies, even at its early stage.
Proteomics International managing director Dr Richard Lipscombe said: “This is a significant achievement because the USA is the largest and most advanced healthcare market in the world. Securing patent protection for our diagnostic technology there is a key step in our commercialisation pathway and provides a strong foundation for potential partnerships, licencing, and regulatory advancement.”
The recently granted US patent, titled ‘Glycoprotein Biomarkers for Esophageal Adenocarcinoma and Barrett’s Esophagus and Uses Thereof’, secures intellectual property protection until 28 February 2036.
Patent coverage for PromarkerEso now spans key jurisdictions, including Australia, China, Hong Kong, Europe and the USA, opening the door to commercial sales in the world’s largest healthcare markets, through direct sales, partnerships and licensing deals.
With rising EAC incidence linked to diet and other lifestyle factors, the relatively straightforward predictive Proteomics test addresses an urgent need for less invasive diagnostics to improve patient outcomes at reduced diagnostic and treatment costs.
The US patent grant strengthens Proteomics’ global position in precision diagnostics, paving the way for the company’s PromarkerEso test to reach patients at risk of this often-fatal cancer of the upper digestive tract and potentially save lives through earlier intervention.
Is your ASX-listed company doing something interesting? Contact: mattbirney@bullsnbears.com.au
